Schedule 13D ownership disclosure
LENZ THERAPEUTICS INC
Common Stock, par value $0.00001 per share · CUSIP: 52635N103
Event date: 2025-08-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Versant Venture Capital VI, L.P.Reported CIK 0001687880
Shares: 1,400,220 · Class: 4.9%
- Versant Ventures VI GP, L.P.Reported CIK 0001777654
Shares: 1,400,220 · Class: 4.9%
- Versant Ventures VI GP-GP, LLCReported CIK 0001777652
Shares: 1,400,220 · Class: 4.9%
- Versant Vantage II, L.P.Reported CIK 0001832235
Shares: 842,162 · Class: 3.0%
- Versant Vantage II GP, L.P.Reported CIK 0001839790
Shares: 842,162 · Class: 3.0%
- Versant Vantage II GP-GP, LLCReported CIK 0001839789
Shares: 842,162 · Class: 3.0%
- Versant Venture Capital VII, L.P.Reported CIK 0001750266
Shares: 1,033,412 · Class: 3.6%
- Versant Ventures VII GP, L.P.Reported CIK 0001777655
Shares: 1,033,412 · Class: 3.6%
- Versant Ventures VII GP-GP, LLCReported CIK 0001777656
Shares: 1,033,412 · Class: 3.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-110483
- Form type
- SCHEDULE 13D/A
- Filer
- LENZ Therapeutics, Inc.
- CIK
- CIK 1815776
- Filed
- Aug 20, 2025
- Reporting period
- Aug 18, 2025
- Description
- Schedule 13D beneficial ownership